General Information of Drug (ID: DMW34B1)

Drug Name
Motixafortide Drug Info
Synonyms BL-8040
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Approved [1]
Acute myeloid leukaemia 2A60 Phase 2 [2]
Myelodysplastic syndrome 2A37 Phase 2 [3]
Pancreatic cancer 2C10 Phase 2 [3]
Cross-matching ID
PubChem CID
91865076
ChEBI ID
CHEBI:145536
CAS Number
CAS 664334-36-5
TTD Drug ID
DMW34B1

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-X-C chemokine receptor type 4 (CXCR4) TTBID49 CXCR4_HUMAN Antagonist [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
C-X-C chemokine receptor type 4 (CXCR4) DTT CXCR4 7.415 8.304 6.284 6.972
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Multiple myeloma
ICD Disease Classification 2A83
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
C-X-C chemokine receptor type 4 (CXCR4) DTT CXCR4 7.10E-15 -0.4 -0.69
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217159
2 ClinicalTrials.gov (NCT02502968) BL-8040 Addition to Consolidation Therapy in AML Patients.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. November 15, 2013; Blood: 122 (21).